Platelet Glycoprotein Iib/Iiia Inhibitors in Cardiovascular Disease

ISBN-13: 9781588291851 / Angielski / Twarda / 2003 / 476 str.

A. Michael Lincoff; Michael A. Lincoff; A. Michael Lincoff

Opis

One of the most important developments in the field of cardiovascular medicine over the last two decades has been recognition of the key role played by arterial thrombosis in the pathogenesis of acute coronary syndromes, ischemic complications of percutane ous coronary revascularization, and coronary and peripheral atherosclerosis. The phar macologic armamentarium directed against vascular thrombosis has thus expanded substantially during that time, with development of new fibrinolytic agents, low-molecu lar-weight heparins, direct thrombin inhibitors, antagonists to platelet activation, and the platelet glycoprotein lIb/IlIa inhibitors. Though clinical investigations of these com pounds have been marked by failures as well as successes, there is little doubt that enhanced antithrombotic therapies have markedly improved the outcome of patients undergoing coronary revascularization or with acute coronary syndromes. Glycoprotein IIblIlIa receptor antagonists were introduced into clinical practice to overcome the limitations of approaches that inhibit only individual pathways of platelet activation. Multiple mechanisms of platelet activation in response to different agonists converge on the platelet membrane glycoprotein IIblIlIa complex, the "final common pathway" of platelet aggregation. The clinical hemorrhagic syndrome caused by a rare inherited defect in this receptor (Glanzmann' s thrombasthenia), characterized by muco cutaneous and postsurgical bleeding, but infrequent spontaneous organ (particularly central nervous system) bleeding, suggested that therapeutic inhibition of this receptor might be a potent, yet well-tolerated means of treating thrombotic disorders.

Recenzje

"...provides the reader with extensive and profound information about this new class, based on data from completed and ongoing trials...can be recommended not only to cardiologists but to all clinicians and researchers interested in this field."
-Intensive Care Medicine

Spis treści

Part I. Basic Principles Thrombosis in Acute Coronary Syndromes and Coronary Interventions Thaddeus R. Tolleson and Robert A. Harrington Platelet Adhesion Edward F. Plow Glycoprotein IIb/IIIa in Platelet Aggregation and Acute Arterial Thrombosis Patrick Andre and David R. Phillips Glycoprotein IIb/IIIa Antagonists: Development of Abciximab and Pharmacology of Abciximab Tirofiban, and Eptifibatide, Barry S. Coller Part II. Glycoprotein IIb/IIIa Blockade During Coronary Intervention Abciximab During Percutaneous Coronary Intervention: EPIC, EPILOG, and EPISTENT Trials A. Michael Lincoff Eptifibatide in Coronary Intervention: The IMPACT and ESPRIT Trials Jean-Pierre Dery, J. Conor O'Shea, and James E. Tcheng Tirofiban in Interventional Cardiology: The RESTORE and TARGET Trials Nicholas Valettas and Howard C. Herrmann Overview of the Glycoprotein IIb/IIIa Interventional Trials A. Michael Lincoff and Eric J. Topol Part III. Glycoprotein IIb/IIIa Blockade for Acute Ischemic Syndromes The Use of Abciximab in Therapy-Resistant Unstable Angina: Clinical and Angiographic Results of the CAPTURE Pilot Trial and the CAPTURE Study Marcel J. B. M. van den Brand and Maarten L. Simoons Unstable Angina Trials: PARAGON, PURSUIT, PRISM, PRISM-PLUS, and GUSTO-IV David J. Moliterno Platelet Glycoprotein IIb/IIIa Inhibitors and an Invasive Strategy Christopher P. Cannon Glycoprotein IIb/IIIa Receptor Blockade in Myocardial Infarction: Adjunctive Therapy to Percutaneous Coronary Interventions Franz-Josef Neumann Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction: Adjunctive Therapy to Fibrinolysis Sorin J. Brener Part IV. Practical Issues and Future Applications Economics of Glycoprotein IIb/IIIa Inhibition Daniel B.Mark Platelet Monitoring and Interaction of Glycoprotein IIb/IIIa Antagonists with Other Antiplatelet Agents Steven R. Steinhubl Platelet Glycoprotein IIb/IIIa Antagonists: Their Interaction with Low-Molecular-Weight Heparins and Direct Thrombin Inhibitors Amol S. Bapat, Naji Yazbek, and Neal S. Kleiman Oral Agents L. Kristin Newby Platelet Glycoprotein IIb/IIIa Inhibitors: Effects Beyond the Platelet Dean J. Kereiakes and Pascal J. Goldschmidt-Clermont Cerebrovascular Interventions Leslie Cho and Jay S. Yadav Cerebrovascular Aspects of Glycoprotein IIb/IIIa Receptor Inhibitors Cathy A. Sila Evolution of Drug Development in Evidence-Based Medicine: Summary and the Future David E. Kandzari, David F. Kong, and Robert M. Califf Index

Blurb

A. Michael Lincoff takes advantage of critically important new knowledge arising from recent clinical trials to update and expand his acclaimed Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. This substantially enhanced Second Edition contains new chapters on the role of GPIIb/IIIa blockade during acute coronary syndromes, on outcomes with chronic oral GPIIb/IIIa blockade following acute coronary syndromes, and on fibrinolytic therapy during acute myocardial infarctions. Additional enhancements include revised findings from the latest trials of GPIIb/IIIa inhibition during percutaneous coronary intervention, discussion of GPIIb/IIIa blockade with other platelet and thrombin inhibitors, and a review of the potential effects beyond inhibition of platelet aggregation. The book also explains the scientific basis of this therapy, evaluates its benefits and risks for patients, and summarizes detailed data from its various clinical trials.
Comprehensive and definitive, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, Second Edition offers physicians, cardiologists, emergency room doctors, and basic scientists a complete and authoritative review of the state-of-the-art in glycoprotein IIb/IIIa receptor inhibitor use today.